Download Files:
Products Details
Product Description
– NAQ is a potent and selective μ opioid receptor partial agonist, with a Ki of 0.55 nM. NAQ shows selectivity for Mu opioid receptor over the δ receptor (Ki=132.50 nM) and the κ receptor (Ki=26.45 nM). NAQ can be used for the research of opioid withdrawal or dependence[1].
Web ID
– HY-151811
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C30H31N3O4
References
– [1]Li G, et, al. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem. 2009 Mar 12;52(5):1416-27.|[2]Altarifi AA, et, al. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2015 Feb;232(4):815-24.|[3]P. Pagare P, et, al. Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment. ACS Pharmacol. Transl. Sci. 2022, 5, 11, 1197-1209.
Molecular Weight
– 497.58
SMILES
– O=C(C1=CC2=C(C=N1)C=CC=C2)N[C@H]3[C@@H]4[C@]56C7=C(O4)C(O)=CC=C7C[C@@H](N(CC8CC8)CC6)[C@@]5(O)CC3
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Opioid Receptor
Isoform
– δ Opioid Receptor/DOR;κ Opioid Receptor/KOR;μ Opioid Receptor/MOR
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
